awmsg logo



fosaprepitant (IVEMEND®)


Reference No. 3789

Publication date:
04/12/2018


Appraisal information

fosaprepitant (IVEMEND®) 150 mg powder for solution for infusion


Company: Merck Sharp & Dohme Ltd
BNF category: Gastro-intestinal system
NMG meeting date: 10/10/2018
AWMSG meeting date: 14/11/2018
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 2018
Ratification by Welsh Government: 03/12/2018

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

Fosaprepitant (IVEMEND®) is recommended as an option for use within NHS Wales for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in patients aged 6 months to less than 18 years of age. Fosaprepitant is given as part of a combination therapy.
AWMSG Secretariat Appraisal Report (ASAR)
Download
Final Appraisal Recommendation (FAR)
Download